DRUG DEVELOPMENT OF ONC392, A NOVEL CTLA-4 INHIBITOR IN ADVANCED RENAL CANCER

$2,064,247FY2025Defense Health AgencyDOD

Regents Of The University Of Michigan

Investigators

View source on USAspending →